Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05970627
Other study ID # IIT20230033C-R1
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 28, 2023
Est. completion date July 28, 2029

Study information

Verified date July 2023
Source First Affiliated Hospital of Zhejiang University
Contact Jiren Yu
Phone 0086-0571-87237931
Email yujr0909@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date July 28, 2029
Est. primary completion date July 28, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Informed Consent Form (ICF). 2. Participants were ambulatory male or female. Age: = 18 years and = 80 years old. 3. Histopathologically confirmed gastric or esophagogastric junction adenocarcinoma. 4. Epstein-Barr Virus-associated Gastric or Esophagogastric Junction Adenocarcinoma, which was determined by in situ hybridization (ISH) test of endoscopic biopsy specimen. 5. cT2-4bN+/-, M0 according to the American Joint Committee on Cancer and Union for International Cancer Control (AJCC-UICC) TNM classification for carcinoma of the stomach (8th edition). 6. Participants had Eastern Cooperative Oncology Group (ECOG) performance status scores of 0-1 within 7 days before the first dose of study treatment. 7. Life expectancy = 6 months. 8. Agreement of providing baseline and surgical specimens for biomarker analysis. 9. The functions of the vital organs meet requirements as follows (within 14 days before the first dose of study treatment, meanwhile, participants had not received treatment of recombinant human thrombopoietin or granulocyte stimulating factor): 1). Hematological function - White blood cell count (WBC): 3.5 × 10^9/L ~12.0 × 10^9/L - Absolute neutrophil count (ANC) = 1.5 × 10^9/L - Platelet count (PLT) = 100 × 10^9/L - Hemoglobin (Hb) = 90g/L. 2). Hepatic function - Total bilirubin (TBIL) = 1.5 × ULN (upper limit of normal); -Aspartate aminotransferase (AST) = 2.5 × ULN; - Alanine aminotransferase (ALT) = 2.5 × ULN; - Albumin (ALB) = 30g/L. 3). Renal function - Creatinine (Cr) = 1.5 × ULN, or creatinine clearance = 60 ml/min for those with creatinine level > 1.5 × ULN. 4). Coagulation function - International normalized ratio (INR) = 1.5; - Prothrombin time (PT) and activated partial thromboplastin time (APTT) = 1.5 × ULN. 10. Female participants of childbearing age must meet requirements: urine or serum pregnancy test must be negative within 7 days before the first dose of study treatment, and she must agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of toripalimab, or 180 days after the last dose of chemotherapy, whichever is longer, and should not be breastfeeding. Male participants must meet requirements: agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of toripalimab, or 180 days after the last dose of chemotherapy, whichever is longer). Exclusion Criteria: 1. HER2-positive status defined as either IHC score of 3+ or IHC 2+ with amplification proven by fluorescent in situ hybridization (FISH) based on pretreatment endoscopic biopsies. 2. Prior systemic therapy for treatment of gastric cancer (surgery, chemotherapy, radiotherapy, targeted therapy or immunotherapy). 3. Previous or concurrent have other active malignant tumors within the past 5 years (except for basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer or cervical cancer or breast cancer in situ that has undergone curative therapy). 4. Participants with gastric outlet obstruction, or unable to oral take, or severe gastrointestinal bleeding. 5. Myocardial infarction within 6 months before the first dose of study treatment, uncontrolled angina, arrhythmia which need medical intervention (including but not limited to cardiac pacemaker), congestive heart failure (New York Heart Association (NYHA) class III or IV). 6. Existence of chronic diarrhea (watery diarrhea: = 5 times per day). 7. Participants with active infection within 14 days before the first dose of study treatment which need medical intervention. 8. Participants with active tuberculosis. 9. Previous or concurrent diagnosed with interstitial lung disease by imaging or symptoms. 10. Any of the following test is positive: Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface Antigen (HBsAg), or Hepatitis C Virus (HCV) antibody. 11. Participants who need long-term systemic steroid therapy (> 10 mg/d prednisone equivalent) or any other form of immunosuppressive therapy within 14 days before the first dose of study treatment or during the study period. 12. Concurrent or previous have severe allergic reaction to any antibody based drugs. 13. Existence of any concurrent autoimmune disease, excepting participants with diabetes mellitus type I, hypothyroidism requiring only hormone replacement therapy. 14. Receive live vaccines within 28 days before the first dose of study treatment or during the study period, excepting inactivated viral vaccines for seasonal influenza. 15. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation. 16. Existence of systemic disease that is difficult to control despite treatment with several agents, for example, diabetes mellitus, hypertension, etc. 17. Existence of other serious physical or mental diseases or serious laboratory abnormalities that may increase the risk of participating in the study. Participants who were judged unsuitable as subjects of this trial by investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Toripalimab
Perioperative Toripalimab, 240 mg IV infusion
Oxaliplatin
Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
S1
S-1 orally intake as perioperative chemotherapy

Locations

Country Name City State
China The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou Zhejiang
China The Second Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou Zhejiang
China Huzhou Central Hospital Huzhou Zhejiang
China Lishui Central Hospital Lishui Zhejiang
China Ningbo First Hospital Ningbo Zhejiang
China Ningbo Medical Center LiHuiLi Hospital Ningbo Zhejiang
China Ningbo Second Hospital Ningbo Zhejiang
China Taizhou Hospital Taizhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Yu jiren

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of pathological complete responses (pCR) Percentage of patients with pCR referring to the total number of enrolled and eligible patients, as evaluated centrally by a reference pathologist. From enrollment to surgery after pre-operative treatment (up to approximately 36 months)
Secondary Overall survival The duration of overall survival (OS) will be determined by measuring the time interval from enrollment to the end of follow up or death from any cause From randomization to the last follow-up or death from any cause (up to approximately 72 months)
Secondary Progression-free survival Progression-free survival (PFS) was defined as the time from randomization to the last follow-up or the time of disease progression or relapse or death from any cause. From randomization to the last follow-up or the time of disease progression or relapse or death from any cause (up to approximately 72 months)
Secondary The incidences and types of adverse events (AE) and severe adverse events (SAE) The incidences and severity of adverse events that occur during treatment will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.3 From enrollment to 90-day after the last dose administration (up to approximately 39 months)
See also
  Status Clinical Trial Phase
Completed NCT00982592 - Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT04077255 - EGFR-targeted Therapy for Gastric Cancer Phase 2
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT00098527 - FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer Phase 2
Active, not recruiting NCT03647969 - Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer Phase 2
Terminated NCT00871273 - Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma Phase 4
Recruiting NCT05729646 - Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT05315830 - A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric Phase 1
Active, not recruiting NCT01095120 - Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer Phase 2
Completed NCT00062374 - Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction Phase 2
Active, not recruiting NCT02202759 - A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction Phase 2
Recruiting NCT01962519 - Early Oral Feeding After Total Gastrectomy for Cancer N/A
Completed NCT00607594 - Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT06121700 - Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer Phase 2
Terminated NCT03722108 - Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas Phase 1/Phase 2
Recruiting NCT05715931 - Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT02678182 - Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial Phase 2
Completed NCT01640782 - Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Phase 3
Recruiting NCT05872685 - Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) Phase 2